Solvay increases offer for Innogenetics
This article was originally published in Scrip
Executive Summary
Solvay Pharmaceuticalshas increased its bid to buy all the shares of Belgian biotech company Innogeneticsfrom €177.6 million ($280 million) to €200.7 million in a cash offer. The increased bid counters a €188 million offer put forward by the San Diego-based company Gen-Probelast month.